Tom graduated University of Brighton with a BA (Hons) degree in Broadcast Journalism, leaving as the valedictorian of the class of 2015. His final year projects and dissertation were nominated for, and won, several awards, whilst he was also the Editor-in-Chief of the university’s news site during his time at Brighton. After previously writing for a property magazine, Tom joined the Proactive team in January 2016.
Mathew Dunn will fill the void left by Helen Ashton’s sudden departure earlier this year
The aim of part two is to study the efficacy and safety of the SNG001 inhaler in up to 120 COPD patients with a confirmed respiratory viral infection
Liberum analyst Yuen Low says it is still early on in graphene’s development, but he has “no doubt” over its “wonder material” status and its potential further down the line
The biopharmas will work together to develop Hemogenyx’s AHC technology, while Orgenesis will invest at least US$1mln in Hemogenyx through a convertible loan
Directa’s Planar Thermal Circuit technology will be used in 10,000 workwear garments made by the unnamed Italian customer
Revenues are expected to rise 13% to £2.10mln, driven by a rise in new and higher value customer deals
This time around, the investment is centred on Hemogenyx’s Hu-PHEC technology - a cell replacement product candidate that is being developed to generate cancer-free, patient-matched blood stem cells after transplantation into the patient
IQ-AI reckons it can eliminate the need for gadolinium-based contrast agents in MRI scans, saving healthcare systems money and avoiding the emerging toxicity concerns
Of course if you’ve already done so, this article probably doesn’t apply to you…
Sometimes a cheap stock is cheap for a reason, not just because it’s good value…
The Rookie Investors has still got the Fever(tree), but would he have done had he set a stop-loss?
As I venture into the world of equity trading, here’s the background to my story and where I’m at now